From TheBodyPro:
Fewer than half of cisgender women on oral antiretroviral therapy expressed an interest in trying injectable HIV treatment, a U.S. survey found. […] Researchers surveyed 1,078 cisgender women living with HIV in nine U.S. urban areas during 2020-2021 about their interest in long-acting injectable HIV treatment. Currently, only cabotegravir/rilpivirine (Cabenuva) is approved in the U.S. for this purpose.
Read more: https://www.thebodypro.com/article/twihr-2024-survey-interest-long-acting-art-women
